Top 5 Stocks to Buy Now
→ Trump’s secret China deal (From Porter & Company) (Ad)tc pixel
NASDAQ:CELU

Celularity Q1 2025 Earnings Report

Celularity logo
$0.76 +0.01 (+0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$0.76 +0.00 (+0.13%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Celularity EPS Results

Actual EPS
-$1.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$5.74 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q1 2025
Date
8/29/2025
Time
After Market Closes
Conference Call Date
Friday, August 29, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Celularity's Q1 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Celularity's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Celularity Earnings Headlines

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental ...
June 5, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/celularity-and-fountain-life-announce-availability-of-cenplacel-l-for-investigational-use-under-new-florida-law-establishing-scalable-pathway-for-advancement-of-placental-derived-cell-therapies-1036224894
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306696/0/en/celularity-and-fountain-life-announce-availability-of-cenplacel-l-for-investigational-use-under-new-florida-law-establishing-scalable-pathway-for-advancement-of-placental-derived-c.html
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.tc pixel
June 22 at 1:00 AM  |  Weiss Ratings (Ad)
Celularity Releases CEO Letter to Shareholders
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3306393/0/en/celularity-releases-ceo-letter-to-shareholders.html
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3305991/0/en/celularity-appoints-rick-gonzalez-as-chief-commercial-officer.html
Celularity Receives Nasdaq Notice Regarding Form 10-Q
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303835/0/en/celularity-receives-nasdaq-notice-regarding-form-10-q.html
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells. Among its lead investigational candidates is a placental-derived NK cell therapy being evaluated in both oncology and immuno-infectious disease settings. Celularity also explores exosome-based approaches to deliver therapeutic proteins and RNA payloads to specific tissues.

Founded by Dr. Robert L. Hariri—who previously established and led Celgene’s cellular therapeutic research efforts—Celularity went public in April 2021 via a special purpose acquisition company (SPAC) transaction and now trades on the Nasdaq under the symbol CELU. The company is headquartered in Florham Park, New Jersey, with research and manufacturing operations designed to support scalable production of its cell therapy candidates.

Under the leadership of President and Chief Executive Officer Robert L. Hariri, M.D., Ph.D., Celularity brings together a team of experts in cell biology, process development and clinical research. The company maintains collaborations with academic centers and industry partners to advance its portfolio through clinical trials, with the goal of delivering novel, off-the-shelf therapies to patients worldwide.

View Celularity Profile
Earnings Tools